Frumil: Complete Professional Guide

• INN (International Nonproprietary Name): Furosemide and Amiloride Hydrochloride.
• Brand Names Available In Canada (English): Not specified.
• ATC Code: C03EB01.
• Forms & Dosages: Tablet, 40 mg furosemide + 5 mg amiloride, oral, scored for splitting.
• Manufacturers In Canada (English): Sanofi (primary originator); Canadian manufacturers not specified.
• Registration Status In Canada (English): Not specified.
• OTC / Rx Classification: Prescription only (Rx/POM) in major markets; Canadian classification not specified in supplied data.

Major 2022–2025 Canadian & Global Studies

Worried about what the recent research says on fixed‑dose furosemide/amiloride combos?

High‑quality randomised controlled trials specifically on the fixed‑dose 40 mg/5 mg furosemide/amiloride tablet remain limited between 2022 and 2025.

Most high‑evidence work in this period concerns loop diuretics such as furosemide in acute decompensated heart failure and outpatient diuretic stewardship rather than brand‑specific combo trials.

Real‑world pharmacoepidemiology from 2022–24 emphasises the risk–benefit balance in older adults, the importance of electrolyte monitoring, and deprescribing where appropriate.

Regulatory product monographs from MHRA (UK), HPRA (Ireland) and Medsafe (New Zealand) continue to be primary sources for data on the fixed combination.

Clinical effect is principally driven by furosemide natriuresis with amiloride mitigating potassium loss in routine dosing.

Typical starting regimens cited in product literature use 1 tablet (40 mg/5 mg) in the morning with titration to 2 tablets/day if required.

Maximum amiloride exposure should not exceed 20 mg/day as per available monographs.

Contemporary safety surveillance highlights electrolyte monitoring — especially potassium — and renal function checks in elderly patients on multiple medications.

Pharmacists should use these findings to guide counselling on dosing, monitoring and deprescribing opportunities.

Clinical Mechanism Of Action

Can a single tablet both remove fluid and protect potassium levels?

Frumil pairs furosemide, a loop diuretic, with amiloride, a potassium‑sparing diuretic, to increase urine output while reducing urinary potassium loss.

Furosemide works by inhibiting the Na+‑K+‑2Cl− cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, producing potent natriuresis and diuresis.

Amiloride blocks epithelial sodium channels (ENaC) in the distal nephron, which reduces renal potassium secretion.

The pharmacodynamic interplay yields effective fluid removal while attenuating the tendency toward hypokalaemia caused by loop diuretics.

That protective effect can, however, raise the risk of hyperkalaemia when amiloride is combined with RAAS blockers such as ACE inhibitors or ARBs.

The tablet is an oral, scored 40 mg/5 mg formulation with standard absorption characteristics and no special cold‑chain requirements.

Renal function and electrolytes should be monitored to guide initial dosing and subsequent titration.

Scope Of Approved & Off‑Label Use

Is Frumil officially approved in Canada and how is it used off‑label?

The supplied product information lists authorisations in the UK (MHRA), Ireland (HPRA) and New Zealand (Medsafe) but does not confirm a Canadian market authorisation or a Drug Identification Number (DIN).

In major markets the product is prescription‑only and carries ATC code C03EB01 for the furosemide + amiloride combination.

Canadian clinicians should check Health Canada’s Drug Product Database for a DIN and consult provincial formulary listings before procurement or prescribing.

In Canadian practice, loop diuretics paired with potassium‑sparing agents are commonly used to manage congestive heart failure‑related oedema and cirrhotic ascites where potassium balance is a concern.

Fixed combinations like the 40/5 tablet are less often first‑line for hypertension, and off‑label use should follow specialist guidance.

Pediatric use of the fixed combo is uncommon and generally reserved for specialist paediatric prescribing when data support it.

Older adults require cautious titration due to comorbidities and polypharmacy risks.

Dosage Strategy

How should dosing be started and adjusted safely?

Product monographs from available jurisdictions recommend an initial adult dose of one tablet (40 mg furosemide + 5 mg amiloride) in the morning.

If clinically required, dosing may be increased to two tablets per day, typically divided AM and noon according to guidance.

The amiloride component should not exceed 20 mg/day, which corresponds to a maximum of four tablets daily.

Tablets are scored to allow splitting where finer titration is required.

In heart failure or oedema, individualise dose to clinical response with outpatient titration guided by weight, blood pressure and repeat electrolytes.

Renal impairment is a key consideration: the combination is contraindicated in anuria and severe renal failure, and should be used cautiously in mild to moderate impairment with frequent labs.

Elderly patients should start at the lowest effective dose and be titrated slowly because of increased sensitivity and concomitant medications.

Children are not routinely recommended for this fixed formulation and require specialist dosing if used.

Safety Protocols

What safety checks must be in place when a patient starts Frumil?

Absolute contraindications include anuria, hyperkalaemia, Addison’s disease and known allergy to furosemide, amiloride, sulfonamides or sulfonylureas.

Pregnancy and breastfeeding should be avoided unless a clear benefit outweighs risk and a prescriber documents rationale.

Common adverse effects reported in post‑market data include increased urination, mild dehydration and dizziness, especially on standing.

Laboratory changes can include hypokalaemia or hyponatraemia due to the loop diuretic effect, although amiloride reduces urinary potassium loss.

When combined with RAAS inhibitors, clinicians must watch for hyperkalaemia; renal function can decline in elderly patients on multiple drugs.

Rare events include rash, hepatic enzyme changes and raised uric acid leading to gout flares in susceptible patients.

Pharmacists should ensure baseline and follow‑up electrolytes and renal panels are arranged and documented.

Interaction Mapping

Which foods and drugs increase risk when taking this combination?

High dietary sodium blunts the effect of diuretics, so counsel patients on sodium reduction to preserve efficacy.

Amiloride increases the risk of hyperkalaemia, so patients should be cautious with potassium‑rich foods such as bananas, potatoes and orange juice and avoid potassium salt substitutes unless advised.

Key drug interactions flagged by regulators include ACE inhibitors, ARBs and ARNIs for additive hyperkalaemia risk when used with amiloride.

Potassium supplements and potassium‑sparing agents should not be co‑administered without close monitoring.

NSAIDs can reduce diuretic efficacy and impair renal perfusion, increasing the risk of renal impairment.

Lithium clearance may be reduced, raising lithium toxicity risk if serum levels are not monitored.

Digoxin risk of arrhythmia increases if electrolyte disturbances occur, so ensure potassium and magnesium are stable.

Pharmacy practice should include medication reviews and provincial drug monitoring checks when these combinations are prescribed.

Patient Experience Analysis

What do patients typically notice when switched to a fixed furosemide/amiloride tablet?

Direct Canadian survey data on Frumil are sparse in public datasets, but broader diuretic surveys of elderly outpatients from 2020–2024 highlight urinary frequency, nocturia and dizziness as the most frequent complaints.

Patients value a predictable potassium profile when switching to combination products that mitigate hypokalaemia risk.

Community pharmacies report common counselling points: take the tablet in the morning to avoid nocturia, show the tablet to the pharmacist for identification and monitor blood tests as instructed.

Patients often mention tablet appearance when confirming identity; the tablet is orange, scored and marked "FRUMIL" on one side.

Forum feedback varies: many report effective oedema control while others stress the inconvenience of ongoing lab monitoring.

Adherence improves with simpler once‑daily regimens, pharmacist follow‑up, and coverage under provincial plans where available.

Distribution & Pricing Landscape

How available is Frumil across Canadian pharmacies and online?

The product is prescription‑only and supply depends on manufacturer distribution and local licensing; Sanofi is the originator and distribution varies by country.

In Canada, pharmacies will dispense if the product is authorised or will offer generic or alternative products where available.

Licensed Canadian online pharmacies require a prescription and must comply with provincial pharmacy regulations for shipping and bilingual labelling.

Cross‑provincial shipping is subject to provincial college rules and pharmacies must follow each province’s dispensing standards.

Provincial drug plans such as the Ontario Drug Benefit, BC PharmaCare and RAMQ may or may not list the product; coverage and copay depend on DIN status and provincial formularies.

Cross‑border purchasing from the United States can result in lower prices for generics but carries risks including non‑equivalent formulations, lack of a Canadian DIN and importation limits.

Patients are advised to consult their Canadian pharmacist before importing medicines to avoid formulation or safety problems.

In our online pharmacy, frumil is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Alternative Options

What alternatives exist if Frumil is unavailable or unsuitable?

Comparable fixed combinations and alternatives include Moduretic (amiloride + hydrochlorothiazide) and Amifru where marketed.

Aldactazide (spironolactone + hydrochlorothiazide) provides a different potassium‑sparing mechanism via aldosterone antagonism.

Prescribers may also order separate furosemide and amiloride tablets to allow flexible dose titration and independent adjustment of each agent.

Pros of fixed combos like the 40/5 tablet include convenience and reduced hypokalaemia risk compared with loop diuretic alone.

Cons include reduced dosing flexibility and a clearer risk of hyperkalaemia when combined with RAAS inhibitors.

Separate agents allow independent titration but increase pill burden and may challenge adherence.

Real formulary choices in Canada are driven by DIN status, provincial coverage and pharmacy stock decisions.

Regulatory Status

How do Canadian regulatory steps affect access and labelling?

To market in Canada a product must pass Health Canada review and receive a Drug Identification Number (DIN).

The supplied product information shows regulatory listings in MHRA, HPRA and Medsafe but does not include Health Canada data in the provided material.

Clinicians and pharmacists should confirm DIN and the Canadian product monograph on Health Canada’s Drug Product Database before clinical use.

Canadian regulations mandate bilingual labelling (English/French) and specific consumer safety information on marketed products.

Provincial formularies require DIN referencing for reimbursement and pharmacists must follow provincial college dispensing guidance.

Adverse events for Canadian patients should be reported via MedEffect Canada.

Practical actions for prescribers include verifying DIN status, ensuring bilingual patient leaflets where required and checking provincial benefit listings prior to prescribing.

Consolidated FAQ

Is Frumil available in Canada?

Check Health Canada’s Drug Product Database for a DIN; if a DIN is not listed in that database, pharmacists can dispense equivalent furosemide + amiloride alternatives or prescribe separate agents.

How should I take Frumil to minimise night‑time urination?

Take the standard tablet in the morning; if a divided dosing schedule is needed, avoid late afternoon or evening doses to reduce nocturia.

Will Frumil affect other heart medicines?

Yes—exercise caution with ACE inhibitors, ARBs or ARNIs due to additive hyperkalaemia risk, and with NSAIDs, digoxin and lithium for renal or electrolyte interactions.

Do provincial plans cover Frumil?

Coverage varies by province; check your provincial formulary (Ontario Drug Benefit, BC PharmaCare, RAMQ) and the DIN to determine eligibility and copayment.

What should I do if I miss a dose?

Take the missed dose when you remember unless it is close to the next scheduled dose; do not double the dose to catch up and seek urgent care for severe dehydration or dizziness.

Visual Guide

What images and infographics help patients follow treatment and procurement steps?

Dosage Flowchart: Start one tablet in the morning, reassess weight and electrolytes in 48–72 hours, consider increasing to two tablets per day if needed, and do not exceed four tablets per day (amiloride limit 20 mg/day).

Provincial Coverage Map: Include icons for Ontario Drug Benefit, BC PharmaCare and RAMQ with a checklist to confirm DIN and reimbursement eligibility.

Purchase Channels: In‑store (Shoppers Drug Mart, Rexall, London Drugs, Jean Coutu) versus licensed Canadian online pharmacies, with prescription requirement and bilingual labelling reminders.

Tablet Appearance Visual: Orange, scored tablet marked "FRUMIL" on one side to aid patient identification.

Include a QR code linking patients to the product monograph and MedEffect Canada reporting page for quick access to safety information.

Storage & Transport

How should households and pharmacies store and ship Frumil?

Store below 25°C (77°F) and protect tablets from moisture and direct light in the original packaging.

Keep medicines out of reach of children and pets and use pharmacy take‑back programs for disposal according to provincial guidance.

Frumil tablets do not require cold‑chain storage; standard ambient transport is appropriate per the product monograph.

For online orders, sealed blister packs or bottles protect tablets from moisture during shipping.

Licensed Canadian pharmacies must follow shipping standards, include bilingual labelling and provide counselling notes with prescription deliveries.

When importing products, patients risk inconsistently labelled items and lack of a Canadian DIN, so consult a community pharmacist before purchasing abroad.

Guidelines For Proper Use

What practical advice do Canadian pharmacists give to patients starting this combination?

Take the tablet in the morning to reduce nocturia whenever possible.

Monitor weight daily, check blood pressure regularly and arrange electrolyte and renal function tests as directed by the prescriber.

Avoid potassium supplements and potassium‑containing salt substitutes unless explicitly approved by the prescriber.

Bring the orange, scored tablet marked "FRUMIL" to the pharmacy to confirm product identity if switching brands or importing.

Document provincial formulary status and provide bilingual counselling to meet patient needs in English and French where required.

Follow provincial heart failure pathways for initiation and titration, and report adverse events to MedEffect Canada.

Delivery Across Canada (English)

Final Notes From The Pharmacist

Patients often ask whether fixed combinations are safer than separate pills.

Fixed combinations can reduce hypokalaemia risk from loop diuretics while simplifying dosing, but they reduce dose flexibility compared with separate prescriptions for furosemide and amiloride.

Always confirm product identity, monitor electrolytes and renal function, and check provincial coverage before ordering.

For safety concerns or symptoms such as severe dizziness, fainting, muscle weakness or palpitations, seek urgent medical care.

Report adverse events through MedEffect Canada and keep your pharmacist informed of all medicines, supplements and over‑the‑counter products you use.